Administration of Huperzine A exerts antidepressant-like activity in a rat model of post-stroke depression

Pharmacology Biochemistry and Behavior

Volumn 158, Issue , 2017, Pages 32-38

  Du, Yuan ^a,c   Liang, Haiyue ^b   Zhang, Leiming ^c   Fu, Fenghua ^a,c  

^a SHANDONG UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b Yantai Center for Food and Drug Control and Test   (China)

^c YANTAI UNIVERSITY   (China)

Author keywords

Cognitive function; Huperzine A; Neurological function; Neurotransmitter; Post stroke depression

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DOPAMINE; HUPERZINE A; NORADRENALIN; SEROTONIN; SEROTONIN 1A RECEPTOR; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; ALKALOID; ANTIDEPRESSANT AGENT; SESQUITERPENE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; COGNITION; CONTROLLED STUDY; DOPAMINE BRAIN LEVEL; FORCED SWIM TEST; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIPPOCAMPAL TISSUE; HIPPOCAMPUS; INCLINED BEAM WALKING TEST; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MORRIS WATER MAZE TEST; NONHUMAN; NORADRENALIN BRAIN LEVEL; POST-STROKE DEPRESSION; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RAT MODEL; REARING; SEROTONIN BRAIN LEVEL; SUCROSE PREFERENCE TEST; UPREGULATION; WESTERN BLOTTING; ANIMAL; CEREBROVASCULAR ACCIDENT; COMPLICATION; DEPRESSION; DISEASE MODEL; DRUG EFFECTS; METABOLISM; SPRAGUE DAWLEY RAT;

ALKALOIDS; ANIMALS; ANTIDEPRESSIVE AGENTS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; DEPRESSION; DISEASE MODELS, ANIMAL; HIPPOCAMPUS; MALE; NEUROTRANSMITTER AGENTS; PREFRONTAL CORTEX; RATS; RATS, SPRAGUE-DAWLEY; SESQUITERPENES; STROKE;

EID: 85020244846     PISSN: 00913057     EISSN: 18735177     Source Type: Journal    
DOI: 10.1016/j.pbb.2017.06.002     Document Type: Article

References (32)

1. Bonhomme, N., Esposito, E., Involvement of serotonin and dopamine in the mechanism of action of novel antidepressant drugs: a review. J. Clin. Psychopharmacol. 18:6 (1998), 447–454.
2. Bradberry, J.C., Fagan, S.C., Gray, D.R., Moon, Y.S., New perspectives on the pharmacotherapy of ischemic stroke. J. Am. Pharm. Assoc. 44:2 Suppl. 1 (2004), S46–S56.
3. Cheng, Y., Su, Q., Shao, B., Cheng, J., Wang, H., Wang, L., Lin, Z., Ruan, L., ZhuGe, Q., Jin, K., 17β-Estradiol attenuates poststroke depression and increases neurogenesis in female ovariectomized rats. Biomed. Res. Int., 2013, 2013, 392434.
4. Clark, R.E., Zola, S.M., Squire, L.R., Impaired recognition memory in rats after damage to the hippocampus. J. Neurosci. 20:23 (2000), 8853–8860.
5. Davidson, R.J., Pizzagalli, D., Nitschke, J.B., Putnam, K., Depression: perspectives from affective neuroscience. Annu. Rev. Psychol. 53 (2002), 545–574.
6. Detke, M.J., Rickels, M., Lucki, I., Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology 121:1 (1995), 66–72.
7. Hows, M.E., Lacroix, L., Heidbreder, C., Organ, A.J., Shah, A.J., High-performance liquid chromatography/tandem mass spectrometric assay for the simultaneous measurement of dopamine, norepinephrine, 5-hydroxytryptamine and cocaine in biological samples. J. Neurosci. Methods 138:1–2 (2004), 123–132.
8. Huang, M., Ichiwaka, J., Li, Z., Dai, J., Meltzer, H.Y., Augmentation by citalopram of risperidone-induced monoamine release in rat prefrontal cortex. Psychopharmacology 185:3 (2006), 274–281.
9. Ishrat, T., Pillai, B., Soliman, S., Fouda, A.Y., Kozak, A., Johnson, M.H., Ergul, A., Fagan, S.C., Low-dose candesartan enhances molecular mediators of neuroplasticity and subsequent functional recovery after ischemic stroke in rats. Mol. Neurobiol. 51:3 (2015), 1542–1553.
10. Koizumi, J., Yoshida, Y., Nakazawa, T., Ooneda, G., Experimental studies of ischemic brain edema: a new experimental model of cerebral embolism in rats in which recirculation can be introduced in the ischemic area. Jpn. J. Stroke 8 (1986), 1–8.
11. Leonard, B.E., New approaches to the treatment of depression. J. Clin. Psychiatry 57:Suppl. 4 (1996), 26–33.
12. Lin, B., Levy, S., Raval, A.P., Perez-Pinzon, M.A., Defazio, R.A., Forebrain ischemia triggers GABAergic system degeneration in substantia nigra at chronic stages in rats. Cardiovasc. Psychiatry Neurol., 2010, 2010, 506952.
13. López-Figueroa, A.L., Norton, C.S., López-Figueroa, M.O., Armellini-Dodel, D., Burke, S., Akil, H., López, J.F., Watson, S.J., Serotonin 5-HT1A, 5-HT1B, and 5-HT2A receptor mRNA expression in subjects with major depression, bipolar disorder, and schizophrenia. Biol. Psychiatry 55:3 (2004), 225–233.
14. Mao, X.Y., Cao, D.F., Li, X., Yin, J.Y., Wang, Z.B., Zhang, Y., Mao, C.X., Zhou, H.H., Liu, Z.Q., Huperzine A ameliorates cognitive deficits in streptozotocin-induced diabetic rats. Int. J. Mol. Sci. 15:5 (2014), 7667–7683.
15. Meilin, S., Machicao, F., Elmlinger, M., Treatment with actovegin improves spatial learning and memory in rats following transient forebrain ischaemia. J. Cell. Mol. Med. 18:8 (2014), 1623–1630.
16. Nibuya, M., Morinobu, S., Duman, R.S., Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J. Neurosci. 15:11 (1995), 7539–7547.
17. Nomura, S., Kagawa, Y., Kida, H., Maruta, Y., Imoto, H., Fujii, M., Suzuki, M., Effects of intrathecal baclofen therapy on motor and cognitive functions in a rat model of cerebral palsy. J. Neurosurg. Pediatr. 9:2 (2012), 209–215.
18. Pin-Barre, C., Laurin, J., Felix, M.S., Pertici, V., Kober, F., Marqueste, T., Matarazzo, V., Muscatelli-Bossy, F., Temprado, J.J., Brisswalter, J., Decherchi, P., Acute neuromuscular adaptation at the spinal level following middle cerebral artery occlusion-reperfusion in the rat. PLoS One, 9(2), 2014, e89953.
19. Porritt, M.J., Andersson, H.C., Hou, L., Nilsson, Å., Pekna, M., Pekny, M., Nilsson, M., Photothrombosis-induced infarction of the mouse cerebral cortex is not affected by the Nrf2-activator sulforaphane. PLoS One, 7(7), 2012, e41090.
20. Radley, J.J., Jacobs, B.L., 5-HT1A receptor antagonist administration decreases cell proliferation in the dentate gyrus. Brain Res. 955:1–2 (2002), 264–267.
21. Rampello, L., Chiechio, S., Nicoletti, G., Alvano, A., Vecchio, I., Raffaele, R., Malaguarnera, M., Prediction of the response to citalopram and reboxetine in post-stroke depressed patients. Psychopharmacology 173:1–2 (2004), 73–78.
22. Robinson, R.G., Poststroke depression: prevalence, diagnosis, treatment, and disease progression. Biol. Psychiatry 54:3 (2003), 376–387.
23. Robinson, R.G., Jorge, R.E., Post-stroke depression: a review. Am. J. Psychiatry 173:3 (2016), 221–231.
24. Shirayama, Y., Chen, A.C., Nakagawa, S., Russell, D.S., Duman, R.S., Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J. Neurosci. 22:8 (2002), 3251–3261.
25. Sugo, N., Hurn, P.D., Morahan, M.B., Hattori, K., Traystman, R.J., DeVries, A.C., Social stress exacerbates focal cerebral ischemia in mice. Stroke 33:6 (2002), 1660–1664.
26. Wang, R., Yan, H., Tang, X.C., Progress in studies of huperzine A. Acta Pharmacol. Sin. 27:1 (2006), 1–26.
27. Wang, S.H., Zhang, Z.J., Guo, Y.J., Teng, G.J., Chen, B.A., Decreased expression of serotonin 1A receptor in the dentate gyrus in association with chronic mild stress: a rat model of post-stroke depression. Psychiatry Res. 170:2–3 (2009), 245–251.
28. Wang, S.H., Zhang, Z.J., Guo, Y.J., Sui, Y.X., Sun, Y., Involvement of serotonin neurotransmission in hippocampal neurogenesis and behavioral responses in a rat model of post-stroke depression. Pharmacol. Biochem. Behav. 95:1 (2010), 129–137.
29. Wiart, L., Petit, H., Joseph, P.A., Mazaux, J.M., Barat, M., Fluoxetine in early poststroke depression: a double-blind placebo-controlled study. Stroke 31:8 (2000), 1829–1832.
30. Zhang, H.Y., Zheng, C.Y., Yan, H., Wang, Z.F., Tang, L.L., Gao, X., Tang, X.C., Potential therapeutic targets of huperzine A for Alzheimer's disease and vascular dementia. Chem. Biol. Interact. 175:1–3 (2008), 396–402.
31. Zheng, W., Xiang, Y.Q., Ungvari, G.S., Chiu, F.K., H, Ng. C., Wang, Y., Xiang, Y.T., Huperzine A for treatment of cognitive impairment in major depressive disorder: a systematic review of randomized controlled trials. Shanghai Arch. Psychiatry 28:2 (2016), 64–71.
32. Zhou, J., Zhang, H.Y., Tang, X.C., Huperzine A attenuates cognitive deficits and hippocampal neuronal damage after transient global ischemia in gerbils. Neurosci. Lett. 313:3 (2001), 137–140.